Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $4.43 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.6% in the second quarter, Holdings Channel reports. The fund owned 48,523 shares of the medical equipment provider’s stock after acquiring an additional 2,997 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Zimmer Biomet were worth $4,426,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ZBH. Ameriprise Financial Inc. lifted its holdings in Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after acquiring an additional 1,488,918 shares during the last quarter. Nuveen LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter worth approximately $155,891,000. Alyeska Investment Group L.P. bought a new stake in Zimmer Biomet during the 1st quarter worth approximately $101,294,000. Finally, Dodge & Cox increased its holdings in Zimmer Biomet by 2.3% during the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after purchasing an additional 446,018 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Up 0.5%

Shares of NYSE ZBH opened at $89.10 on Wednesday. Zimmer Biomet Holdings, Inc. has a 52-week low of $85.33 and a 52-week high of $114.44. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The stock has a market cap of $17.66 billion, a P/E ratio of 21.68, a P/E/G ratio of 2.29 and a beta of 0.67. The firm has a 50 day moving average price of $97.95 and a 200 day moving average price of $96.84.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the company posted $1.74 earnings per share. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were issued a dividend of $0.24 per share. The ex-dividend date was Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Barclays reduced their price target on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research lowered their price objective on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $109.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.